Upfront surgery is the gold standard for patients with resectable pancreatic cancer however it is rarely curative. Adjuvant chemotherapy offers the best strategy to improve overall survival however the major challenges are rapid disease progression and poor tolerance. Neoadjuvant approach has demonstrated favourable trends in patient outcomes and is routine in borderline resectable disease. This presentation will address recent updates in the neoadjuvant space with a focus on a multidisciplinary care model.